Choose a language and wait for the translated text.
Speaking to analysts post first quarter FY27 results, Richard Ascroft, CEO of Sun Pharma’s North America business, said, "We are seeing good momentum in Leqselvi." which crossed 1,000 prescribers in June and has gained coverage across most payer programmes in the US. However, seasonal factors affecting another derma drug Levulan Kerastick, weighed on sequential growth of the specialty portfolio.
Sun Pharma’s Leqselvi tops 1000 prescribers in US; seasonal shifts hits Levulan | PharmaVoice
